Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab (1680 mg) for reimbursement as a monotherapy treatment option for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. The regimen further states that patients with EGFR mutations or an ALK fusion oncogene are required to have received prior tyrosine kinase inhibitor therapy.
This is written in the approval document as:
Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy.
Citation
Atezolizumab 1680mg Monotherapy - 28 Day, 2024, version number 10a, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/593-atezolizumab-1680mg-monotherapy-28-day.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | EGFR somatic variants | Non-Small Cell Lung Cancer | Atezolizumab | |
| Sensitivity (+) | v::ALK | Non-Small Cell Lung Cancer | Atezolizumab |